AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC

José Baselga AstraZeneca headshot
José Baselga, executive vice president of oncology R&D at AstraZeneca (AstraZeneca)

The FDA is set to decide whether to approve AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate (ADC) in the second quarter of next year. AstraZeneca landed the PDUFA date for [fam-] trastuzumab deruxtecan after the FDA accepted its approval submission for priority review.

[Fam-] trastuzumab deruxtecan arrives at the FDA on the back of a phase 2 trial that hit its primary endpoint. AstraZeneca and its partner Daiichi are yet to share a detailed look at the results, stating only that they are clinically meaningful and confirm the efficacy seen in phase 1, when the ADC achieved a 60% response rate in heavily pretreated HER2+ breast cancer patients. 

The phase 1 data led AstraZeneca to pay $1.35 billion and commit to $5.5 billion in milestones for the chance to jointly develop [fam-] trastuzumab deruxtecan with Daiichi. The size of the upfront means AstraZeneca may need excellent safety and efficacy data to make the deal a financial success. 

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

If approved, [fam-] trastuzumab deruxtecan will initially be used some way down the HER2+ breast cancer treatment pathway. Subjects enrolled in the phase 2 had previously taken two other drugs against HER2: Roche’s aging blockbuster Herceptin and Kadcyla, the currently preferred second-line treatment option. Kadcyla, like [fam-] trastuzumab deruxtecan, is a HER2 ADC.

To justify the size of the deal, AstraZeneca will likely need to establish [fam-] trastuzumab deruxtecan higher up the treatment pathway. That could be achievable if the efficacy results seen in phase 1 are replicated and the data are free from safety red flags. 

Roche established Kadcyla as a second-line treatment by achieving a response rate of 41% but was unable to generate strong enough data to supplant Herceptin in first-line use, causing sales to fail to live up to analysts' expectations. 

Suggested Articles

ADC Therapeutics nearly went through the entire alphabet before trying, twice, to get off an IPO. Now, it’s looking to become a commercial biotech.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Vaccinex is developing a drug it hopes could be the first disease-modifying treatment for Huntington disease, but that program hit a snag in phase 2.